- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07948044
Prospective Validation of the MASA Score for Detection of Previously Unknown Atrial Fibrillation (MASA-AF)
MASA (Metabolic-Atrial-Septal-Assessment) Score for Selecting Patients for Extended ECG Monitoring: A Prospective, Blinded, Single-Center Diagnostic Accuracy Cohort Study
The MASA (Metabolic-Atrial-Septal-Assessment) score is a simple 0-8 point score built from five routinely available variables: estimated glomerular filtration rate, serum triglycerides, absence of atrial septal aneurysm, left atrial diameter, and TAPSE. In a retrospective development cohort (n=246), a score of 5 or more identified patients with atrial fibrillation (AF). This prospective study will test, in consecutive patients with cardiovascular disease or stroke without known AF admitted to the Intensive Care Unit, whether a MASA score of 5 or more identifies those in whom AF is detected by continuous ECG monitoring. The score, its threshold, and the primary outcome are fixed before enrollment and will not be changed.
Přehled studie
Postavení
Intervence / Léčba
Detailní popis
Background: Undetected paroxysmal atrial fibrillation (AF) is a major preventable cause of stroke. Extended ECG monitoring is effective but resource-intensive; a simple score could help select patients who need it most.
Study phases: The study was approved by the Ethics Committee of the Special Hospital for Cerebrovascular Diseases "Sveti Sava" (No. 03/4310, 30 October 2026) under the title "Development of the MASA score for assessing the probability of atrial fibrillation in a retrospective cohort of cardiology patients and its prospective validation in the intensive care unit: a single-center study." Phase 1 (retrospective score development, n=246) is completed. This registration covers Phase 2, the prospective validation in consecutive patients with cardiovascular disease or stroke (ischemic stroke, hemorrhagic stroke, or transient ischemic attack) admitted to the Intensive Care Unit.
Pre-specified score (locked before enrollment): eGFR <60 mL/min/1.73 m² (CKD-EPI 2021) = 1 point; triglycerides <=1.2 mmol/L = 1 point; atrial septal aneurysm ABSENT on echocardiography = 3 points; left atrial diameter >=46 mm = 1 point; TAPSE <=17 mm = 2 points. Score range 0-8. Positive screen = score >=5.
Procedures: Consecutive eligible patients undergo blood sampling (serum creatinine, triglycerides) and transthoracic echocardiography (left atrial diameter, TAPSE, interatrial septum assessment) shortly after ICU admission, with heart rhythm recorded at the time of echocardiography. The MASA score is calculated by an investigator not involved in rhythm assessment. All patients, regardless of score, undergo continuous ECG monitoring during the ICU stay. ECG recordings are assessed by two readers blinded to the MASA score and its components; disagreements are resolved by a third reader. AF is defined as an episode of at least 30 seconds.
Sample size: At least 61 patients with confirmed AF are required for a precise estimate of sensitivity (target 100). Enrollment continues until at least 61 (target 100) patients with confirmed AF have been enrolled; the anticipated total enrollment is approximately 700 patients, assuming a 10% AF detection rate.
Analysis: Primary-sensitivity and specificity of MASA >=5 with 95% confidence intervals. Secondary-positive and negative predictive values, area under the ROC curve, comparison with age and CHA2DS2-VASc (DeLong test), decision curve analysis, and number of patients monitored per detected AF. Pre-specified sensitivity analysis: serum creatinine >=90 umol/L instead of eGFR. Reporting will follow STARD 2015 and TRIPOD+AI 2024.
Typ studie
Zápis (Odhadovaný)
Kontakty a umístění
Studijní kontakt
- Jméno: Dejan Munjiza, MD, MSc
- Telefonní číslo: +381608018437
- E-mail: munjizad@gmail.com
Studijní místa
-
-
-
Belgrade, Srbsko, 11000
- Special Hospital for Cerebrovascular Diseases "Sveti Sava"
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Metoda odběru vzorků
Studijní populace
Consecutive adult patients with cardiovascular disease or stroke, without previously documented atrial fibrillation, admitted to the Intensive Care Unit of the Special Hospital for Cerebrovascular Diseases "Sveti Sava", Belgrade, Serbia.
Popis
Inclusion Criteria:
- Age 18 years or older
- Consecutive admission to the Intensive Care Unit with cardiovascular disease or stroke (ischemic stroke, hemorrhagic stroke or transient ischemic attack)
- Sinus rhythm on the admission 12-lead ECG
- Transthoracic echocardiography and blood tests (serum creatinine, triglycerides) feasible shortly after admission
Exclusion Criteria:
- Any previously documented atrial fibrillation or atrial flutter
- Atrial fibrillation or atrial flutter on the admission ECG
- Permanent pacemaker or implantable cardioverter-defibrillator
- Mechanical mitral valve prosthesis or moderate-to-severe mitral stenosis
- Inadequate echocardiographic window for measurement of left atrial diameter, TAPSE or assessment of the interatrial septum
- Expected duration of continuous ECG monitoring shorter than 24 hours
Studijní plán
Jak je studie koncipována?
Detaily designu
- Observační modely: COHORT
- Časové perspektivy: PROSPECTIVE
Kohorty a intervence
Skupina / kohorta |
Intervence / Léčba |
|---|---|
|
ICU patients with cardiovascular disease or stroke without known AF
Consecutive adult patients with cardiovascular disease or stroke (ischemic stroke, hemorrhagic stroke or transient ischemic attack), without previously documented atrial fibrillation, admitted to the Intensive Care Unit. All participants have the MASA score calculated and undergo continuous ECG monitoring during the ICU stay. |
Calculation of the MASA score (range 0-8) from routinely collected data: eGFR <60 mL/min/1.73 m2 = 1 point; triglycerides <=1.2 mmol/L = 1 point; atrial septal aneurysm absent on echocardiography = 3 points; left atrial diameter >=46 mm = 1 point; TAPSE <=17 mm = 2 points. A score >=5 is considered a positive screen. The score does not influence patient management; all patients undergo continuous ECG monitoring regardless of score. |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Sensitivity and Specificity of MASA Score >=5 for Detection of Atrial Fibrillation
Časové okno: From ICU admission to ICU discharge (up to 30 days)
|
Sensitivity and specificity (with 95% confidence intervals) of a MASA score >=5 for atrial fibrillation detected by continuous ECG monitoring. Atrial fibrillation is defined as an episode lasting at least 30 seconds, confirmed by two readers blinded to the MASA score and its components; disagreements are resolved by a third reader. |
From ICU admission to ICU discharge (up to 30 days)
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Positive and Negative Predictive Values of MASA Score >=5
Časové okno: From ICU admission to ICU discharge (up to 30 days)
|
Positive and negative predictive values (with 95% confidence intervals) of a MASA score >=5 for atrial fibrillation detected by continuous ECG monitoring. |
From ICU admission to ICU discharge (up to 30 days)
|
|
Discriminative Performance of the MASA Score
Časové okno: From ICU admission to ICU discharge (up to 30 days)
|
Area under the ROC curve (with 95% confidence interval) of the MASA score for atrial fibrillation, compared with age and CHA2DS2-VASc score using the DeLong test. |
From ICU admission to ICU discharge (up to 30 days)
|
|
Clinical Net Benefit of MASA-Guided Monitoring
Časové okno: From ICU admission to ICU discharge (up to 30 days)
|
Net benefit of selecting patients for extended ECG monitoring by MASA score >=5, assessed by decision curve analysis. |
From ICU admission to ICU discharge (up to 30 days)
|
|
Number of Patients Monitored per Detected Atrial Fibrillation
Časové okno: From ICU admission to ICU discharge (up to 30 days)
|
Number of patients who would need extended ECG monitoring to detect one case of atrial fibrillation when monitoring is restricted to patients with MASA score >=5. |
From ICU admission to ICU discharge (up to 30 days)
|
Spolupracovníci a vyšetřovatelé
Vyšetřovatelé
- Vrchní vyšetřovatel: Dejan Munjiza, MD, MSc, Special Hospital for Cerebrovascular Diseases "Sveti Sava"
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
- Cerebrovaskulární poruchy
- Onemocnění mozku
- Onemocnění centrálního nervového systému
- Nemoci nervového systému
- Cévní onemocnění
- Kardiovaskulární choroby
- Patologické procesy
- Srdeční choroba
- Arytmie, srdeční
- Mrtvice
- Patologické stavy, příznaky a symptomy
- Cévní mozková příhoda
- Hemoragická mrtvice
- Fibrilace síní
Další identifikační čísla studie
- MASA-AF-2026
- 03/4310 (Jiný identifikátor: Ethics Committee, SB Sveti Sava, Belgrade)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
De-identified individual participant data underlying the published results, together with the analysis code, will be made available.
Časový rámec sdílení IPD
After publication of the primary results, for at least 5 years.
Kritéria přístupu pro sdílení IPD
Available to qualified researchers on reasonable request to the principal investigator, for non-commercial research purposes.
Typ podpůrných informací pro sdílení IPD
- PROTOKOL STUDY
- MÍZA
- ANALYTIC_CODE
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .